[go: up one dir, main page]

WO2006102899A3 - Traitement ou prevention du prurit - Google Patents

Traitement ou prevention du prurit Download PDF

Info

Publication number
WO2006102899A3
WO2006102899A3 PCT/DK2006/000180 DK2006000180W WO2006102899A3 WO 2006102899 A3 WO2006102899 A3 WO 2006102899A3 DK 2006000180 W DK2006000180 W DK 2006000180W WO 2006102899 A3 WO2006102899 A3 WO 2006102899A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
oxaprozin
closely related
related compound
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DK2006/000180
Other languages
English (en)
Other versions
WO2006102899A2 (fr
Inventor
Morten Sloth Weidner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astion Development AS
Original Assignee
Astion Development AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200702026A priority Critical patent/EA200702026A1/ru
Priority to CA002603297A priority patent/CA2603297A1/fr
Priority to AU2006228870A priority patent/AU2006228870A1/en
Priority to JP2008503367A priority patent/JP2008534527A/ja
Priority to MX2007012051A priority patent/MX2007012051A/es
Priority to BRPI0609653-0A priority patent/BRPI0609653A2/pt
Application filed by Astion Development AS filed Critical Astion Development AS
Publication of WO2006102899A2 publication Critical patent/WO2006102899A2/fr
Publication of WO2006102899A3 publication Critical patent/WO2006102899A3/fr
Priority to IL186021A priority patent/IL186021A0/en
Anticipated expiration legal-status Critical
Priority to NO20075199A priority patent/NO20075199L/no
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des méthodes et des médicaments convenant pour le traitement du prurit en général ou d'un prurit causé directement ou indirectement par des maladies dermatologiques, dont le traitement d'une affection sous-jacente, par administration topique sur la peau ou par administration systèmique à un sujet d'oxaprozine ou bien d'un composé étroitement apparenté ou d'un sel de ce composé.
PCT/DK2006/000180 2005-03-30 2006-03-30 Traitement ou prevention du prurit Ceased WO2006102899A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA002603297A CA2603297A1 (fr) 2005-03-30 2006-03-30 Traitement ou prevention du prurit
AU2006228870A AU2006228870A1 (en) 2005-03-30 2006-03-30 Oxaprozin or closely related compound for the treatment and prevention of
JP2008503367A JP2008534527A (ja) 2005-03-30 2006-03-30 そう痒の治療および予防のためのオキサプロジンまたは密接に関連する化合物
MX2007012051A MX2007012051A (es) 2005-03-30 2006-03-30 Tratamiento o prevencion del prurito.
BRPI0609653-0A BRPI0609653A2 (pt) 2005-03-30 2006-03-30 tratamento ou prevenção de prurido
EA200702026A EA200702026A1 (ru) 2005-03-30 2006-03-30 Лечение или предупреждение зуда
IL186021A IL186021A0 (en) 2005-03-30 2007-09-18 Oxaprozin or closely related compound for the treatment and prevention of pruritus
NO20075199A NO20075199L (no) 2005-03-30 2007-10-11 Treatment or prevention of pruritus

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
DKPA200500438 2005-03-30
DKPA200500438 2005-03-30
DKPA200500437 2005-03-30
DKPA200500437 2005-03-30
US69477405P 2005-06-27 2005-06-27
DKPA200500949 2005-06-27
DKPA200500948 2005-06-27
DKPA200500948 2005-06-27
DKPA200500949 2005-06-27
US60/694,774 2005-06-27
US69504005P 2005-06-28 2005-06-28
US60/695,040 2005-06-28

Publications (2)

Publication Number Publication Date
WO2006102899A2 WO2006102899A2 (fr) 2006-10-05
WO2006102899A3 true WO2006102899A3 (fr) 2006-12-28

Family

ID=36215671

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/DK2006/000180 Ceased WO2006102899A2 (fr) 2005-03-30 2006-03-30 Traitement ou prevention du prurit
PCT/DK2006/000178 Ceased WO2006102898A2 (fr) 2005-03-30 2006-03-30 Traitement des eczemas
PCT/DK2006/000181 Ceased WO2006102900A1 (fr) 2005-03-30 2006-03-30 Compositions dermatologiques et sels destines au traitement de maladies dermatologiques

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/DK2006/000178 Ceased WO2006102898A2 (fr) 2005-03-30 2006-03-30 Traitement des eczemas
PCT/DK2006/000181 Ceased WO2006102900A1 (fr) 2005-03-30 2006-03-30 Compositions dermatologiques et sels destines au traitement de maladies dermatologiques

Country Status (12)

Country Link
EP (3) EP1707201A1 (fr)
JP (3) JP2008534527A (fr)
KR (3) KR20080011280A (fr)
AU (3) AU2006228869A1 (fr)
BR (3) BRPI0609653A2 (fr)
CA (3) CA2603297A1 (fr)
EA (3) EA200702023A1 (fr)
EC (3) ECSP077843A (fr)
IL (3) IL186020A0 (fr)
MX (3) MX2007012051A (fr)
NO (3) NO20075199L (fr)
WO (3) WO2006102899A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0821537D0 (en) * 2008-11-25 2008-12-31 Union Life Sciences Ltd Therapeutic target
WO2017045081A1 (fr) * 2015-09-18 2017-03-23 Delivra Inc. Formulations transdermiques pour l'administration d'ains à base d'acide propionique et acétique et leur utilisation dans le traitement de maladies et de pathologies sensibles aux ains
WO2018031529A1 (fr) * 2016-08-08 2018-02-15 Avedro, Inc. Systèmes et procédés de traitements d'un œil par réticulation
IL265719B2 (en) 2016-10-25 2024-01-01 Ticure Ltd Fabp4 as a therapeutic target in skin diseases
KR20200097297A (ko) * 2017-12-07 2020-08-18 더마반트 사이언시즈 게엠베하 Pde-4 억제제의 국소 연고 제형 및 피부 병태 치료에서의 이의 용도
RU2685436C1 (ru) * 2018-06-22 2019-04-18 ЗАО "ФармФирма "Сотекс" Трансдермальный препарат для лечения и профилактики болезней суставов и мягких тканей
JP7514598B2 (ja) * 2018-12-20 2024-07-11 小林製薬株式会社 皮膚外用組成物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002074290A2 (fr) * 2001-03-15 2002-09-26 Agis Industries (1983) Ltd. Preparations dermatologiques
US20030082226A1 (en) * 1997-08-29 2003-05-01 Samour Carlos M. Non-steroidal antiinflammatory drug formulations for topical application to the skin

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE32084B1 (en) * 1967-06-07 1973-04-04 Wyeth John & Brother Ltd Thiazole derivatives
US3578671A (en) * 1967-11-06 1971-05-11 Wyeth John & Brother Ltd Oxazoles
IE52909B1 (en) * 1981-04-28 1988-04-13 Wyeth John & Brother Ltd Oxazole derivatives
US4659728A (en) * 1985-02-25 1987-04-21 American Home Products Corporation Hydroxy substituted 4,5-diphenyl-2-oxazole propanoic acid
EP0270316A3 (fr) * 1986-12-04 1989-12-06 Pfizer Inc. Compositions topiques contenant des imidazoles 1-substitués et des agents non-steroides anti-inflammatoires pour le traitement de l'acné
US5380738A (en) 1993-05-21 1995-01-10 Monsanto Company 2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US6090834A (en) 1993-05-21 2000-07-18 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
EP0724438A1 (fr) 1993-10-20 1996-08-07 The Boots Company PLC Ibuprofene et flurbiprofene utilises en tant qu'agents antiprurigineux
JPH07316075A (ja) 1994-05-26 1995-12-05 Pola Chem Ind Inc 皮膚外用剤
GB9606429D0 (en) 1996-03-27 1996-06-05 Boots Co Plc Pharmaceutical compositions
JP4185974B2 (ja) * 1996-05-20 2008-11-26 ジー． デイー． サール、 リミテッド、 ライアビリティ、 カンパニー カリウム、ナトリウムおよびトリスオキサプロジン塩医薬組成物
WO2005009342A2 (fr) 2003-07-16 2005-02-03 Pharmacia Corporation Methode de traitement ou de prevention de troubles dermatologiques a l'aide d'un seul inhibiteur de la cyclooxygenase-2 ou en combinaison avec un agent de traitement dermatologique, et compositions contenant ceux-ci
US20050232957A1 (en) 2004-04-14 2005-10-20 Katz Kenneth A Compositions and methods for moisturizing skin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030082226A1 (en) * 1997-08-29 2003-05-01 Samour Carlos M. Non-steroidal antiinflammatory drug formulations for topical application to the skin
WO2002074290A2 (fr) * 2001-03-15 2002-09-26 Agis Industries (1983) Ltd. Preparations dermatologiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ED. BY KATHLEEN PARFITT: "Martindale, The complete drug reference, 32nd Edition", 1999, PHARMACEUTICAL PRESS, LONDON, XP002381108 *

Also Published As

Publication number Publication date
KR20080011280A (ko) 2008-02-01
JP2008534526A (ja) 2008-08-28
MX2007012051A (es) 2008-02-22
WO2006102900A1 (fr) 2006-10-05
ECSP077843A (es) 2008-02-20
NO20075199L (no) 2008-01-02
AU2006228870A1 (en) 2006-10-05
EA200702027A1 (ru) 2008-02-28
EA200702023A1 (ru) 2008-04-28
EP1707201A1 (fr) 2006-10-04
MX2007012052A (es) 2008-02-22
NO20075227L (no) 2007-12-09
WO2006102899A2 (fr) 2006-10-05
ECSP077846A (es) 2008-02-20
IL186022A0 (en) 2008-02-09
EP1707199A1 (fr) 2006-10-04
CA2603297A1 (fr) 2006-10-05
WO2006102898A2 (fr) 2006-10-05
BRPI0609653A2 (pt) 2010-04-20
BRPI0607648A2 (pt) 2009-09-22
IL186021A0 (en) 2008-02-09
BRPI0609535A2 (pt) 2010-04-13
JP2008534528A (ja) 2008-08-28
JP2008534527A (ja) 2008-08-28
IL186020A0 (en) 2008-01-20
WO2006102898A3 (fr) 2006-12-28
NO20075218L (no) 2007-12-27
CA2605121A1 (fr) 2006-10-05
AU2006228869A1 (en) 2006-10-05
EA200702026A1 (ru) 2008-04-28
AU2006228871A1 (en) 2006-10-05
KR20080005525A (ko) 2008-01-14
KR20080005526A (ko) 2008-01-14
EP1707200A1 (fr) 2006-10-04
MX2007012050A (es) 2008-03-11
ECSP077845A (es) 2008-02-20
CA2603300A1 (fr) 2006-10-05

Similar Documents

Publication Publication Date Title
WO2009050506A3 (fr) Combinaison 059
WO2007038459A3 (fr) Composes de carboxyamine et leurs methodes d'utilisation
WO2006091693A3 (fr) Extension de la periode menant a la progression de la maladie ou a la survie chez les patients atteints d'un cancer
WO2007143600A3 (fr) Inhibiteurs de la sheddase combinés avec des substances immunothérapeutiques se liant à cd30 destinés au traitement de maladies associées à cd30
WO2008148074A3 (fr) Inhibiteurs de mtor et methodes de traitement mettant en œuvre ces inhibiteurs
WO2006093348A3 (fr) Procede et composition destines au traitement des maladies vasculaires peripheriques
MY148108A (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2006035237A3 (fr) Procedes et compositions lies a la maladie d'alzheimer
IL190150A0 (en) New pyrimidine derivatives and their use in therapy as well as the use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
WO2009068659A3 (fr) Nouveau traitement de maladies par prédiction d'association médicamenteuse
HK1198869A1 (en) Combination treatments for hepatitis c
WO2008076954A3 (fr) Composés hétérocycliques et procédés d'utilisation de ceux-ci
WO2012050831A3 (fr) Traitement combiné d'affections dermatologiques
IL195472A0 (en) Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
WO2009041663A1 (fr) Agent destiné à la prévention et/ou au traitement de maladies cutanées
WO2009099642A3 (fr) Analyse protéomique de lésions de sclérose en plaques actives
WO2008070010A3 (fr) Rétablissement après une attaque
NO20075199L (no) Treatment or prevention of pruritus
WO2007128564A3 (fr) Utilisation d'un composé présentant une activité rankl
WO2007023154A3 (fr) Utilisation de composes complexes ferriques pour produire un medicament utilise dans le traitement d'etats de deficience ferrique chez des patients atteints de maladie inflammatoire chronique de l'intestin
WO2006124413A3 (fr) Procedes pour traiter un cancer pharmacoresistant
WO2007075923A3 (fr) Traitement de formes de synucleinopathie
WO2007014943A3 (fr) Traitement pour maladies neurologiques
WO2006108682A3 (fr) Substances et compositions pharmaceutiques destinees a inhiber les glyoxalases, et leur utilisation comme agents antifongiques
WO2006053788A3 (fr) Modifications de keratoses seborrheiques et applications associees

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 186021

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 7406/DELNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/012051

Country of ref document: MX

Ref document number: 12007502119

Country of ref document: PH

Ref document number: 562098

Country of ref document: NZ

Ref document number: 2008503367

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200680010823.6

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2603297

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006228870

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 07112251

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2006228870

Country of ref document: AU

Date of ref document: 20060330

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006228870

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 1200702261

Country of ref document: VN

Ref document number: 1020077025180

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: RU

WWE Wipo information: entry into national phase

Ref document number: 200702026

Country of ref document: EA

122 Ep: pct application non-entry in european phase

Ref document number: 06722872

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6722872

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0609653

Country of ref document: BR

Kind code of ref document: A2